Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Inclusion Criteria16

• Age ≥18 years old;
• Signed the informed consent and volunteered to join the study with good compliance;
• , histopathologically confirmed HER2-negative invasive breast cancer (including triple-negative breast cancer; Or Luminal breast cancer, that is, ER/PR positive and HER2 negative) :
• HER2 negative was defined as 0/1+ on standard IHC test; HER2/CEP17 ratio was less than 2.0 or HER2 gene copy number was less than 4.
• ER positive and/or PR positive were defined as the proportion of positively stained tumor cells in all tumor cells ≥1%;
• \. According to the American Joint Committee on Cancer (AJCC) 8th edition TNM stage II-IIIC (T2-T4 plus any N, or any T plus N1-3, M0);
• \. The main organs function well and meet the following standards:
• A) Hemoglobin (HGB)≥90g/L;
• B) Neutrophil absolute value (NEUT)≥1.5×109/L;
• C) Platelet count (PLT)≥ 100×109/L;
• D) leukocyte ≥3.0×109/L;
• E) Total bilirubin \<1.5 ULN (upper limit of normal)
• F) Creatinine \< 1.5×ULN
• G) AST/ALT \< 1.5×ULN;
• \. Cardiac ultrasound: left ventricular ejection fraction (LVEF≥55%);
• \. The investigators determined that the patients were suitable for treatment with bevacizumab.